Literature DB >> 11983298

Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults.

Neil Pendleton1, Anthony Payton, Eelke H van den Boogerd, Fiona Holland, Peter Diggle, Patrick M A Rabbitt, Michael A Horan, Jane Worthington, William E R Ollier.   

Abstract

There is evidence of a genetic influence on the decline in cognitive performance of older adults, although the mechanisms responsible are unknown. A group of 767 subjects of the Manchester University Age and Cognitive Performance longitudinal study volunteer group, followed up from 1985 to the present, were genotyped for apolipoprotein E (APOE). The data from this were related to cross-sectional and longitudinal trends in the Heim intelligence test score (AH4-1) using previously reported random-effects models (Neuropsychologia 39 (2001) 532). There were no significant differences in mean scores for presence compared with absence of the APOE4 or APOE2 genotypes (P=0.48 and P=0.51, respectively). This research does not demonstrate a link between intelligence and APOE genotype in older adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983298     DOI: 10.1016/s0304-3940(02)00135-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

Review 1.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease.

Authors:  Elizabeth W Twamley; Susan A Legendre Ropacki; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2006-09       Impact factor: 2.892

2.  Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.

Authors:  Danielle C Whitehair; Abdullah Sherzai; Jennifer Emond; Rema Raman; Paul S Aisen; Ronald C Petersen; Adam S Fleisher
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

3.  Influences of APOE ε4 and expertise on performance of older pilots.

Authors:  Joy L Taylor; Quinn Kennedy; Maheen M Adamson; Laura C Lazzeroni; Art Noda; Greer M Murphy; Jerome A Yesavage
Journal:  Psychol Aging       Date:  2011-06

4.  The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males.

Authors:  R Srinivasan; Y Davidson; L Gibbons; A Payton; A M T Richardson; A Varma; C Julien; C Stopford; J Thompson; M A Horan; N Pendleton; S M Pickering-Brown; D Neary; J S Snowden; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

5.  Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study.

Authors:  G A Dore; M F Elias; M A Robbins; P K Elias; Z Nagy
Journal:  Diabetologia       Date:  2009-08-20       Impact factor: 10.122

Review 6.  Challenges in phenotype definition in the whole-genome era: multivariate models of memory and intelligence.

Authors:  F W Sabb; A C Burggren; R G Higier; J Fox; J He; D S Parker; R A Poldrack; W Chu; T D Cannon; N B Freimer; R M Bilder
Journal:  Neuroscience       Date:  2009-05-18       Impact factor: 3.590

Review 7.  Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function.

Authors:  Amanda M Di Battista; Nicolette M Heinsinger; G William Rebeck
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  APOE polymorphism, socioeconomic status and cognitive function in mid-life--the Whitehall II longitudinal study.

Authors:  J H Zhao; E J Brunner; M Kumari; A Singh-Manoux; E Hawe; P J Talmud; M G Marmot; S E Humphries
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-07-15       Impact factor: 4.328

Review 9.  Posterior cortical atrophy.

Authors:  Sebastian J Crutch; Manja Lehmann; Jonathan M Schott; Gil D Rabinovici; Martin N Rossor; Nick C Fox
Journal:  Lancet Neurol       Date:  2012-02       Impact factor: 44.182

10.  A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing.

Authors:  G Davies; S E Harris; C A Reynolds; A Payton; H M Knight; D C Liewald; L M Lopez; M Luciano; A J Gow; J Corley; R Henderson; C Murray; A Pattie; H C Fox; P Redmond; M W Lutz; O Chiba-Falek; C Linnertz; S Saith; P Haggarty; G McNeill; X Ke; W Ollier; M Horan; A D Roses; C P Ponting; D J Porteous; A Tenesa; A Pickles; J M Starr; L J Whalley; N L Pedersen; N Pendleton; P M Visscher; I J Deary
Journal:  Mol Psychiatry       Date:  2012-12-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.